Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 08-09-2022 | Alzheimer's Disease | Original Article

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Authors: Jarith L. Ebenau, Denise Visser, Sander C. J. Verfaillie, Tessa Timmers, Mardou S. S. A. van Leeuwenstijn, Mara ten Kate, Albert D. Windhorst, Frederik Barkhof, Philip Scheltens, Niels D. Prins, Ronald Boellaard, Wiesje M. van der Flier, Bart N. M. van Berckel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2023

Abstract

Purpose

The role of cerebral blood flow (CBF) in the early stages of Alzheimer’s disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD).

Methods

We included 187 cognitively normal individuals with SCD from the SCIENCe project (65 ± 8 years, 39% F, MMSE 29 ± 1). Each underwent a dynamic (0–70 min) [¹⁸F]florbetapir PET and T1-weighted MRI scan, enabling calculation of mean binding potential (BP_ND; specific amyloid binding) and R₁ (measure of relative (r)CBF). Eighty-three individuals underwent a second [¹⁸F]florbetapir PET (2.6 ± 0.7 years). Participants annually underwent neuropsychological assessment (follow-up time 3.8 ± 3.1 years; number of observations n = 774).

Results

A low baseline R₁ was associated with steeper decline on tests addressing memory, attention, and global cognition (range betas 0.01 to 0.27, p < 0.05). High BP_ND was associated with steeper decline on tests covering all domains (range betas − 0.004 to − 0.70, p < 0.05). When both predictors were simultaneously added to the model, associations remained essentially unchanged. Additionally, we found longitudinal associations between R₁ and BP_ND. High baseline BP_ND predicted decline over time in R₁ (all regions, range betas_BP×time − 0.09 to − 0.14, p < 0.05). Vice versa, low baseline R₁ predicted increase in BP_ND in frontal, temporal, and composite ROIs over time (range betas_R1×time − 0.03 to − 0.08, p < 0.05).

Conclusion

Our results suggest that amyloid accumulation and decrease in rCBF are two parallel disease processes without a fixed order, both providing unique predictive information for cognitive decline and each process enhancing the other longitudinally.

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRef

Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimers Dement: Diagn Assess Dis Monit. 2017;6:108–21. https://doi.org/10.1016/j.dadm.2016.09.002.CrossRef

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science (New York, NY). 2002;297:353–6. https://doi.org/10.1126/science.1072994.CrossRef

Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat Rev Neurol. 2021;17:157–72. https://doi.org/10.1038/s41582-020-00435-y.CrossRef

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA. 2015;313:1924–38. https://doi.org/10.1001/jama.2015.4668.CrossRef

Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12:723–38. https://doi.org/10.1038/nrn3114.CrossRef

Chen Y, Wolk DA, Reddin JS, Korczykowski M, Martinez PM, Musiek ES, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology. 2011;77:1977–85. https://doi.org/10.1212/WNL.0b013e31823a0ef7.CrossRef

Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer’s disease. Alzheimers Dement: J Alzheimers Assoc. 2012;8:51–9. https://doi.org/10.1016/j.jalz.2011.06.003.CrossRef

Duan W, Sehrawat P, Balachandrasekaran A, Bhumkar AB, Boraste PB, Becker JT, et al. Cerebral blood flow is associated with diagnostic class and cognitive decline in Alzheimer’s disease. J Alzheimers Dis: JAD. 2020;76:1103–20. https://doi.org/10.3233/jad-200034.CrossRef

10.

Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, Wyffels L, Ceyssens S, et al. (18)F-FDG PET, the early phases and the delivery rate of (18)F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: Validation against (15)O-H2O PET. Alzheimers Dement: J Alzheimers Assoc. 2019. https://doi.org/10.1016/j.jalz.2019.05.010.CrossRef

11.

de Eulate RG, Goñi I, Galiano A, Vidorreta M, Recio M, Riverol M, et al. Reduced cerebral blood flow in mild cognitive impairment assessed using phase-contrast MRI. J Alzheimers Dis: JAD. 2017;58:585–95. https://doi.org/10.3233/jad-161222.CrossRef

12.

Michels L, Warnock G, Buck A, Macauda G, Leh SE, Kaelin AM, et al. Arterial spin labeling imaging reveals widespread and Aβ-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2016;36:581–95. https://doi.org/10.1177/0271678x15605847.CrossRef

13.

Gietl AF, Warnock G, Riese F, Kälin AM, Saake A, Gruber E, et al. Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiol Aging. 2015;36:1619–28. https://doi.org/10.1016/j.neurobiolaging.2014.12.036.CrossRef

14.

Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, et al. Lower cerebral blood flow in subjects with Alzheimer’s dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. Alzheimers Dement (Amsterdam, Netherlands). 2017;9:76–83. https://doi.org/10.1016/j.dadm.2017.10.001.CrossRef

15.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, et al. Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer’s disease. J Magn Reson Imaging: JMRI. 2020;51:505–13. https://doi.org/10.1002/jmri.26810.CrossRef

16.

Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, et al. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med: Off Publ Soc Nucl Med. 2008;49:1465–71. https://doi.org/10.2967/jnumed.108.051946.CrossRef

17.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, et al. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment. Brain J Neurol. 2014;137:1550–61. https://doi.org/10.1093/brain/awu043.CrossRef

18.

Bilgel M, Beason-Held L, An Y, Zhou Y, Wong DF, Resnick SM. Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2020;40:288–97. https://doi.org/10.1177/0271678x19830537.CrossRef

19.

Albrecht D, Isenberg AL, Stradford J, Monreal T, Sagare A, Pachicano M, et al. Associations between vascular function and Tau PET are associated with global cognition and amyloid. J Neurosci: Off J Soc Neurosci. 2020;40:8573–86. https://doi.org/10.1523/jneurosci.1230-20.2020.CrossRef

20.

Bangen KJ, Clark AL, Edmonds EC, Evangelista ND, Werhane ML, Thomas KR, et al. Cerebral blood flow and amyloid-β interact to affect memory performance in cognitively normal older adults. Front Aging Neurosci. 2017;9:181. https://doi.org/10.3389/fnagi.2017.00181.CrossRef

21.

Funaki K, Nakajima S, Noda Y, Wake T, Ito D, Yamagata B, et al. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline? Psychogeriatr Off J Japan Psychogeriatr Soc. 2019;19:325–32. https://doi.org/10.1111/psyg.12397.CrossRef

22.

Staffaroni AM, Cobigo Y, Elahi FM, Casaletto KB, Walters SM, Wolf A, et al. A longitudinal characterization of perfusion in the aging brain and associations with cognition and neural structure. Hum Brain Mapp. 2019;40:3522–33. https://doi.org/10.1002/hbm.24613.CrossRef

23.

Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, et al. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease. Eur Radiol. 2017;27:1169–75. https://doi.org/10.1007/s00330-016-4450-z.CrossRef

24.

De Vis JB, Peng SL, Chen X, Li Y, Liu P, Sur S, et al. Arterial-spin-labeling (ASL) perfusion MRI predicts cognitive function in elderly individuals: A 4-year longitudinal study. J Magn Reson Imaging: JMRI. 2018;48:449–58. https://doi.org/10.1002/jmri.25938.CrossRef

25.

Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2019;39:2172–80. https://doi.org/10.1177/0271678x18783628.CrossRef

26.

Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med: Off Publ Soc Nucl Med. 2011;52:393–400. https://doi.org/10.2967/jnumed.110.083683.CrossRef

27.

Hays CC, Zlatar ZZ, Wierenga CE. The utility of cerebral blood flow as a biomarker of preclinical Alzheimer’s disease. Cell Mol Neurobiol. 2016;36:167–79. https://doi.org/10.1007/s10571-015-0261-z.CrossRef

28.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective cognitive impairment cohort (SCIENCe): Study design and first results. Alzheimers Res Ther. 2018;10:76. https://doi.org/10.1186/s13195-018-0390-y.CrossRef

29.

van der Flier WM, Scheltens P. Amsterdam dementia cohort: Performing research to optimize care. J Alzheimers Dis: JAD. 2018;62:1091–111. https://doi.org/10.3233/jad-170850.CrossRef

30.

van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis: JAD. 2014;41:313–27. https://doi.org/10.3233/jad-132306.CrossRef

31.

Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. https://doi.org/10.1002/hbm.10123.CrossRef

32.

Lammertsma AA. Forward to the past: The case for quantitative PET imaging. J Nucl Med: Off Publ Soc Nucl Med. 2017;58:1019–24. https://doi.org/10.2967/jnumed.116.188029.CrossRef

33.

Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279–87. https://doi.org/10.1006/nimg.1997.0303.CrossRef

34.

Verfaillie SCJ, Golla SSV, Timmers T, Tuncel H, van der Weijden CWJ, Schober P et al. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study. J Cereb Blood Flow Metab. 2020; 0271678X20915403. https://doi.org/10.1177/0271678X20915403.

35.

Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD Sr. A Semiautomated method for quantification of F 18 Florbetapir PET Images. J Nucl Med: Off Publ Soc Nucl Med. 2015;56:1736–41. https://doi.org/10.2967/jnumed.114.153494.CrossRef

36.

Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351–6. https://doi.org/10.2214/ajr.149.2.351.CrossRef

37.

Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, et al. Amyloid PET and cognitive decline in cognitively normal individuals: The SCIENCe project. Neurobiol Aging. 2019;79:50–8. https://doi.org/10.1016/j.neurobiolaging.2019.02.020.CrossRef

38.

Park KW, Yoon HJ, Kang DY, Kim BC, Kim S, Kim JW. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer’s disease. Psychiatry Res. 2012;203:201–6. https://doi.org/10.1016/j.pscychresns.2011.12.007.CrossRef

39.

Wolters FJ, Zonneveld HI, Hofman A, van der Lugt A, Koudstaal PJ, Vernooij MW, et al. Cerebral perfusion and the risk of dementia: A population-based study. Circulation. 2017;136:719–28. https://doi.org/10.1161/circulationaha.117.027448.CrossRef

40.

Leeuwis AE, Benedictus MR, Kuijer JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement: J Alzheimers Assoc. 2017;13:531–40. https://doi.org/10.1016/j.jalz.2016.08.013.CrossRef

41.

Korte N, Nortley R, Attwell D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer’s disease. Acta Neuropathol. 2020;140:793–810. https://doi.org/10.1007/s00401-020-02215-w.CrossRef

42.

Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: The amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53–66. https://doi.org/10.1038/s41583-021-00533-w.CrossRef

43.

Matej R, Tesar A, Rusina R. Alzheimer’s disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview. Clin Biochem. 2019;73:26–31. https://doi.org/10.1016/j.clinbiochem.2019.08.005.CrossRef

44.

Visser D, Wolters EE, Verfaillie SCJ, Coomans EM, Timmers T, Tuncel H, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47:3165–75. https://doi.org/10.1007/s00259-020-04831-w.CrossRef

Title: Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
Authors: Jarith L. Ebenau
Denise Visser
Sander C. J. Verfaillie
Tessa Timmers
Mardou S. S. A. van Leeuwenstijn
Mara ten Kate
Albert D. Windhorst
Frederik Barkhof
Philip Scheltens
Niels D. Prins
Ronald Boellaard
Wiesje M. van der Flier
Bart N. M. van Berckel
Publication date: 08-09-2022
Publisher: Springer Berlin Heidelberg
Keywords: Alzheimer's Disease
Alzheimer's Disease
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05958-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2023

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours

Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [18F]FDG lights up the way

New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group